Copyright 2018 Abbott Law Group.
All Rights Reserved.


(904) 292-1111

Call Us For a Free Consultation


(877) 292-1500

Onglyza Lawsuit

Abbott Law Group, P.A. > Onglyza Lawsuit

Onglyza LawsuitIncreased risk of heart failure, congestive heart failure, cardiac failure, and death

If you or someone you love have experienced heart failure, congestive heart failure, cardiac failure or death while taking Onglyza or Kombiglyze XR, please call our lawyers at (877) 292-1500 or fill out the web form.

Manufactured and marketed by Bristol-Myers Squibb along with AstraZeneca, Onglyza (also known as saxagliptin) was approved by the Food and Drug Administration (FDA) on July 31, 2009.  Along with diet and exercise, Onglyza is used for the treatment of Type 2 diabetes in people who do not suffer from diabetic ketoacidosis.  The medication falls in the class of drugs known as DPP-4 inhibitors (also known as dipeptidyl peptidase-4), which force the pancreas to secrete more insulin and inhibit the liver from producing excess sugar.  Onglyza is particularly popular among DPP-4 inhibitors because it does not provoke weight gain like other medications in its class.  The makers of Onglyza made over $820 million in sales of the medication last year alone, and analysts believe that the drug could rake in nearly $2.5 billion in sales by 2018.

Onglyza and Heart Failure

In addition to concerns over pancreatitis and pancreatic cancer, in April 2015, members of the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted to update Onglyza’s label to include an increased risk for heart failure in consumers of the drug.  This vote came after a study done by The New England Journal of Medicine found that rate of hospitalization for heart failure was drastically increased in users of Onglyza compared to those taking the placebo.  This revelation has led to even more consumers filing lawsuits against Bristol-Myers Squibb and AstraZeneca.

Onglyza Joint Pain Side Effects

On August 28, 2015, the FDA issued a safety warning regarding concerns over DPP-4 inhibitors and their capacity to cause severe joint pain.  The FDA stated that DPP-4 inhibitors, including Onglyza, may cause severe and disabling joint pain in users, and added this new warning to the labels of all medications in this class of drugs.  According to the safety warning, patients started developing joint pain from 1 day to years after they started taking a DPP-4 inhibitor.  After the patients discontinued their medication, their symptoms were relieved, typically in less than a month.  The patients who restarted the same medication or another DPP-4 inhibitor developed the severe joint pain again.

Onglyza Side Effects Overview

As you can see, Onglyza and other DPP-4 inhibitors have the capability of causing many severe adverse side effects in users.  The more serious side effects of Onglyza include:

  • Heart Failure,
  • Congestive Heart Failure,
  • Cardiac Failure,
  • Death.

Onglyza also carries the risk of more common side effects, including:

  • Nausea,
  • Vomiting,
  • Sore throat,
  • Headache,
  • Diarrhea,
  • Low blood sugar,
  • Urinary tract infection, and
  • Swelling or fluid retention.

If you are suffering from any of these adverse side effects, it is suggested that you contact your doctor.

Onglyza Lawyer

The attorneys of Abbott Law Group are currently reviewing claims on behalf of those who used Onglyza and were subsequently hospitalized with heart failure, congestive heart failure, or cardiac failure.  Please contact us today to find out if you may be legally entitled to compensation for past and future medical bills, lost wages, pain and suffering, and other damages.  The attorneys of Abbott Law Group have over thirty years of experience trying product liability and personal injury cases, and they know what it takes to go up against powerful corporations.  If your case meets the criteria for eligibility to file Onglyza lawsuit, our attorneys will fight to obtain the maximum compensation to which you may be legally entitled.  Contact us today for a free case evaluation.